Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591686 | 0.91 | AKR1C2 (0.42) | PGRHCAR2NR3C1NR3C2AR | |
| SCHEMBL6931613 | 0.91 | AKR1C2 (0.42) | PGRHCAR2NR3C1NR3C2AR | |
| SCHEMBL7593441 | 0.81 | ALDH1A1 (0.38) | PGRHCAR2ALOX5PTGS2ALDH1A1 | |
| SCHEMBL7969034 | 0.81 | ALDH1A1 (0.38) | PGRHCAR2ALOX5PTGS2ALDH1A1 | |
| SCHEMBL6932901 | 0.78 | PGR (0.41) | PGRHCAR2ALOX5ESR2FTO | |
| SCHEMBL7971858 | 0.77 | MCL1 (0.38) | PGRHCAR2ARPTGER3 | |
| SCHEMBL7984729 | 0.76 | CHRNA1 (0.39) | HCAR2PTGS2ALDH1A1HCAR3 | |
| SCHEMBL6026477 | 0.76 | CHRNA1 (0.39) | HCAR2PTGS2ALDH1A1HCAR3 | |
| SCHEMBL6932241 | 0.75 | PTGER3 (0.36) | PGRARPTGER3ALOX5TDP2 | |
| SCHEMBL6932670 | 0.74 | MDM2 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6265436-B1 | ANTIINFLAMMATORY AGENTS | OXIS THERAPEUTICS INC. | 2001-07-24 | — | — | US | claimed |
| EP-1246811-B1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS ISLE OF MAN LTD (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-6613919-B2 | Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones | OXIS ISLE OF MAN | 2003-09-02 | — | — | US | disclosed |
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | OXIS ISLE OF MAN | 2003-04-03 | — | — | US | disclosed |
| US-6265436-B1 | ANTIINFLAMMATORY AGENTS | OXIS THERAPEUTICS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | ADH1C, SRD5A2, SRD5A1 | PGR 3900/4885HCAR2 75/4885NR3C1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.